valsartan has been researched along with Obesity in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (35.48) | 29.6817 |
| 2010's | 17 (54.84) | 24.3611 |
| 2020's | 3 (9.68) | 2.80 |
| Authors | Studies |
|---|---|
| Chou, CL; Fang, TC; Li, CH | 1 |
| Chen, CH; Chen, CJ; Fang, JY; Huang, TH; Lin, HA | 1 |
| Aroor, AR; Chandrasekar, B; Das, N; DeMarco, VG; Habibi, J; Jia, G; Lastra, G; Lopez-Alvarenga, JC; Mummidi, S | 1 |
| Brink, D | 1 |
| Albrecht, D; Blaak, EE; Engeli, S; Goossens, GH; Hartmann, N; Havekes, B; Heise, T; Jax, T; Jocken, JW; Jordan, J; Kaiser, S; Langenickel, TH; Letzkus, M; May, M; Schaper, N; Schindler, C; Stinkens, R; van der Kolk, BW | 1 |
| Kitzman, DW; Packer, M | 1 |
| Hasan, AU; Hashimoto, T; Ishihara, N; Ishihara, Y; Kamitori, K; Kohno, M; Noma, T; Ohmori, K; Tokuda, M; Yamaguchi, F | 1 |
| Ambrosio, G; Anker, SD; Díez, J; Edelmann, F; Filippatos, GS; Fraser, AG; Gavazzi, A; Gheorghiade, M; Guazzi, M; Hummel, SL; Lam, CS; Levy, D; Maggioni, AP; Metra, M; Paulus, WJ; Pfeffer, MA; Pieske, BM; Senni, M; Smiseth, OA; Solomon, SD; Stewart Coats, AJ; Stough, WG; Tschöpe, C | 1 |
| Akkaya, N; Cakmak, M; Çelik, HT; Demircelik, B; Erdamar, H; Gok, S; Kazanci, F; Yigitoglu, R | 1 |
| Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Santoro, T; Zoppi, A | 1 |
| Brown, RE; Imran, SA; Wilkinson, M | 1 |
| Deedwania, PC; Egan, BM; Jialal, I; Ofili, EO; Purkayastha, D; Raij, L; Samuel, R; Sowers, JR; Zappe, DH | 1 |
| Rudolph, A; Weintraub, HS | 1 |
| Akhtari, S; Andalib, A; Curnew, G; Leclerc, JM; Rigal, R; Tardif, JC; Vaillancourt, M | 1 |
| Circelli, M; Cremonesi, G; Fogari, R; Mugellini, A | 1 |
| Matsuura, K; Mori, Y; Tanaka, T; Utsunomiya, K; Yokoyama, J | 1 |
| Dralova, OV; Ermolaeva, AS; Maksimov, ML | 1 |
| Egan, BM; Purkayastha, D; Raij, L; Samuel, R; Sowers, JR; Zappe, DH | 1 |
| Han, G; Lieberman, K; Meyers, KE; Shi, V; Solar-Yohay, S | 1 |
| Biskupiak, J; Qian, C; Quah, R; Ram, CV; Ramaswamy, K; Russo, PA; Ryan, A | 1 |
| Goto, SN; Mizuno, Y; Takagi, H; Umemoto, T; Yamamoto, H | 1 |
| Ambrosi, P; Andrejak, M; Drici, MD; Herpin, D; Pithois-Merli, I | 1 |
| Bönner, G; Heintz, D; Kandra, A; Khder, Y; Malacco, E; Ruilope, LM | 1 |
| Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A | 1 |
| Boschmann, M; Engeli, S; Jordan, J; Kreuzberg, U; Luft, FC; Sharma, AM; Weidinger, G | 1 |
| Hirata, Y; Hirono, Y; Sugiyama, T; Tateno, T; Tsuchiya, K; Yoshimoto, T | 1 |
| Adams, F; Boschmann, M; Engeli, S; Franke, G; Jordan, J; Klaua, S; Kreuzberg, U; Luft, FC; Scholze, J; Sharma, AM; Weidinger, G | 1 |
| Itoh, Y; Mori, Y; Tajima, N | 1 |
| Davidson, J; Koval, S; Lacourcière, Y; Sharma, AM | 1 |
| Horiuchi, M; Inaba, S; Iwai, M; Mogi, M; Tomono, Y | 1 |
| Dunseath, G; Luzio, SD; Owens, DR | 1 |
8 review(s) available for valsartan and Obesity
| Article | Year |
|---|---|
Heart failure treatment: Keeping up with best practices.
Topics: Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Cardiac Rehabilitation; Cardiac Resynchronization Therapy; Cardiovascular Agents; Defibrillators, Implantable; Diuretics; Drug Combinations; Echocardiography; Heart Failure; Heart-Assist Devices; Humans; Ivabradine; Obesity; Physician's Role; Physicians, Family; Sleep Apnea, Obstructive; Stroke Volume; Tetrazoles; Valsartan | 2018 |
Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2.
Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Drug Therapy, Combination; Glucosides; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Neprilysin; Obesity; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan | 2018 |
New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes.
Topics: Aminobutyrates; Anemia; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Arrhythmias, Cardiac; Biphenyl Compounds; Cardiotonic Agents; Clinical Trials as Topic; Diabetic Angiopathies; Diuretics; Drug Combinations; Exercise Therapy; Heart Failure; Homeostasis; Humans; Hypertension, Pulmonary; Iron Deficiencies; Mineralocorticoid Receptor Antagonists; Molecular Targeted Therapy; Obesity; Observational Studies as Topic; Patient Selection; Phenotype; Phosphodiesterase 5 Inhibitors; Sodium Channel Blockers; Stroke Volume; Tetrazoles; Valsartan; Vascular Stiffness | 2014 |
Combination therapy for managing difficult-to-treat patients with stage 2 hypertension: focus on valsartan-based combinations.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Black or African American; Calcium Channel Blockers; Diuretics; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Obesity; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2011 |
Combination delapril/manidipine as antihypertensive therapy in high-risk patients.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Diabetes Complications; Dihydropyridines; Drug Combinations; Enalapril; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Indans; Irbesartan; Losartan; Nitrobenzenes; Obesity; Olmesartan Medoxomil; Piperazines; Ramipril; Tetrazoles; Valine; Valsartan | 2011 |
[Hypertension, obesity, erectile dysfunction. What kind of drug to choose].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Erectile Dysfunction; Humans; Hypertension; Male; Obesity; Renin-Angiotensin System; Risk Factors; Tetrazoles; Valine; Valsartan | 2011 |
Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Calcium Channel Blockers; Confidence Intervals; Cross-Over Studies; Double-Blind Method; Humans; Hypertension; Hypertension, Renal; Imidazoles; Interleukin-6; Obesity; Prospective Studies; Publication Bias; Randomized Controlled Trials as Topic; Stents; Telmisartan; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2013 |
[The best of clinical pharmacology in 2004].
Topics: Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Diabetes Complications; Humans; Obesity; Tetrazoles; Valine; Valsartan | 2005 |
13 trial(s) available for valsartan and Obesity
| Article | Year |
|---|---|
The effects of angiotensin receptor neprilysin inhibition by sacubitril/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients.
Topics: Adipose Tissue; Adult; Aminobutyrates; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Drug Combinations; Female; Humans; Hypertension; Male; Middle Aged; Neprilysin; Obesity; Proteins; Subcutaneous Fat; Tetrazoles; Transcriptome; Valsartan | 2018 |
The Effects of Valsartan and Amlodipine on the Levels of Irisin, Adropin, and Perilipin.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Proteins; Calcium; Carrier Proteins; Female; Fibronectins; Humans; Hypertension; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Obesity; Peptides; Perilipin-1; Phosphoproteins; Valsartan | 2015 |
Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients.
Topics: Adult; Aged; Amlodipine; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Hypertension; Insulin; Male; Middle Aged; Obesity; Overweight; Prospective Studies; Tetrazoles; Valine; Valsartan | 2008 |
Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Body Mass Index; Calcium Channel Blockers; Diuretics; Drug Therapy, Combination; Female; Glucose Tolerance Test; Humans; Hydrochlorothiazide; Hypertension; Insulin; Male; Middle Aged; Obesity; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Blood Pressure; Female; Glucose; Glucose Tolerance Test; Humans; Hyperinsulinism; Hypertension; Insulin Resistance; Male; Obesity; Telmisartan; Tetrazoles; Valine; Valsartan | 2011 |
Office and ambulatory blood pressure-lowering effects of combination valsartan/hydrochlorothiazide vs. hydrochlorothiazide-based therapy in obese, hypertensive patients.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Comorbidity; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Obesity; Office Visits; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
The efficacy and safety of valsartan in obese and non-obese pediatric hypertensive patients.
Topics: Adolescent; Antihypertensive Agents; Blood Pressure; Child; Comorbidity; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypertension; International Cooperation; Male; Obesity; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Obesity; Risk Factors; Tetrazoles; Valine; Valsartan | 2005 |
Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients.
Topics: Aged; Antihypertensive Agents; Felodipine; Female; Humans; Hypertension; Insulin Resistance; Leptin; Male; Middle Aged; Obesity; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hypertension; Lipids; Male; Middle Aged; Obesity; Sodium Chloride Symporter Inhibitors; Tetrazoles; Valine; Valsartan | 2005 |
The effect of oral glucose loads on tissue metabolism during angiotensin II receptor and beta-receptor blockade in obese hypertensive subjects.
Topics: Adipose Tissue; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Ethanol; Fatty Acids, Nonesterified; Female; Glucose; Glucose Tolerance Test; Glycerol; Humans; Hypertension; Insulin; Kinetics; Lactic Acid; Lipids; Male; Metabolism; Middle Aged; Muscle, Skeletal; Obesity; Tetrazoles; Valine; Valsartan | 2006 |
Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diabetes Mellitus, Type 2; Diastole; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Male; Middle Aged; Obesity; Placebos; Single-Blind Method; Systole; Telmisartan; Tetrazoles; Valine; Valsartan | 2007 |
Acute effects of valsartan on insulin sensitivity in obese, non-hypertensive subjects with and without type 2 diabetes.
Topics: Adolescent; Adult; Antihypertensive Agents; Cross-Over Studies; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Obesity; Tetrazoles; Valine; Valsartan | 2002 |
10 other study(ies) available for valsartan and Obesity
| Article | Year |
|---|---|
Benefits of Valsartan and Amlodipine in Lipolysis through PU.1 Inhibition in Fructose-Induced Adiposity.
Topics: Activating Transcription Factor 3; Adiposity; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Fructose; Humans; Hypertension; Lipase; Lipolysis; Monoacylglycerol Lipases; Obesity; Stearoyl-CoA Desaturase; Tetrazoles; Triglycerides; Valsartan | 2022 |
Self-Nanoemulsifying Drug Delivery System-Containing the Poorly Absorbed Drug - Valsartan in Post-Bariatric Surgery.
Topics: Animals; Bariatric Surgery; Caco-2 Cells; Drug Delivery Systems; Humans; Obesity; Pharmaceutical Preparations; Valsartan | 2023 |
Sacubitril/valsartan inhibits obesity-associated diastolic dysfunction through suppression of ventricular-vascular stiffness.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cytokines; Diabetic Cardiomyopathies; Diastole; Disease Models, Animal; Drug Combinations; Male; Myocardium; Neprilysin; Obesity; Protease Inhibitors; Rats, Zucker; Valsartan; Vascular Stiffness; Ventricular Dysfunction, Left; Ventricular Function, Left | 2021 |
Valsartan ameliorates the constitutive adipokine expression pattern in mature adipocytes: a role for inverse agonism of the angiotensin II type 1 receptor in obesity.
Topics: 3T3-L1 Cells; Active Transport, Cell Nucleus; Adipocytes; Adipokines; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Chlorocebus aethiops; COS Cells; Drug Inverse Agonism; Interleukin-6; Mice; NF-kappa B; Obesity; PPAR gamma; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2014 |
Tissue-specific effects of valsartan on rstn and fiaf gene expression in the ob/ob mouse.
Topics: Angiopoietin-Like Protein 4; Angiopoietins; Angiotensin II Type 1 Receptor Blockers; Animals; Cerebral Cortex; Diabetes Mellitus; Disease Models, Animal; Gene Expression Regulation; Hypothalamus; Intra-Abdominal Fat; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Pituitary Gland; Resistin; RNA, Messenger; Subcutaneous Fat; Tetrazoles; Time Factors; Valine; Valsartan | 2010 |
Determinants of masked hypertension in hypertensive patients treated in a primary care setting.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Cardiovascular Diseases; Comorbidity; Diabetes Complications; Drug Therapy, Combination; Dyslipidemias; Female; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Male; Masked Hypertension; Middle Aged; Obesity; Prevalence; Primary Health Care; Quebec; Risk; Tetrazoles; Valine; Valsartan; White Coat Hypertension | 2012 |
Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Black or African American; Blood Pressure; Diabetes Mellitus; Electronic Health Records; Female; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Male; Middle Aged; Obesity; Primary Health Care; Retrospective Studies; Tetrazoles; Treatment Outcome; Valine; Valsartan; White People; Young Adult | 2011 |
Angiotensin II induces monocyte chemoattractant protein-1 expression via a nuclear factor-kappaB-dependent pathway in rat preadipocytes.
Topics: Adipocytes; Adipose Tissue; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Cell Differentiation; Chemokine CCL2; Humans; Male; NF-kappa B; Nitriles; Obesity; Promoter Regions, Genetic; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfones; Tetrazoles; Thiocarbamates; Transcription, Genetic; Valine; Valsartan | 2006 |
Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity.
Topics: Adipocytes; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Calcium Channel Blockers; Cell Size; Diabetes Mellitus, Type 2; Disease Models, Animal; Insulin; Intra-Abdominal Fat; Male; Obesity; PPAR gamma; Random Allocation; Rats; Rats, Long-Evans; Telmisartan; Tetrazoles; Valine; Valsartan | 2007 |
Blockade of AT1 receptor improves adipocyte differentiation in atherosclerotic and diabetic models.
Topics: Adipocytes, White; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Cell Differentiation; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Gene Deletion; Gene Expression; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Obesity; PPAR gamma; Receptor, Angiotensin, Type 1; Tetrazoles; Valine; Valsartan | 2008 |